Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 4, 2016, Pages 835-841

  Yeh, Ming Lun ^a,b,f   Hsieh, Ming Yen ^a   Huang, Ching I ^d   Huang, Chung Feng ^a,b,e   Hsieh, Meng Hsuan ^a,b   Huang, Jee Fu ^a,b   Dai, Chia Yen ^a,b,f   Chuang, Wan Long ^a,b,f   Yu, Ming Lung ^a,b,c,f  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Center for Infectious Disease and Cancer Research   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^e KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dual infection; HBeAg positive; Hepatitis B; Hepatitis C; Lamivudine

Indexed keywords

HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADD ON THERAPY; ADULT; ARTICLE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL EFFECTIVENESS; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; COINFECTION; COMBINATION DRUG THERAPY; FOLLOW UP; HEPATITIS B; HEPATITIS C; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84963859635     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13203     Document Type: Article

References (24)

1. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004; 126: 1024-9.
2. Chuang WL, Chang WY, Lu SN et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer 1992; 69: 2052-4.
3. Yang JF, Lin CI, Huang JF et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010; 26: 461-9.
4. Raimondo G, Brunetto MR, Pontisso P et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006; 43: 100-7.
5. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995; 22: 1101-8.
6. Dai CY, Yu ML, Chuang WL et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2001; 16: 636-40.
7. Liaw YF, Kao JH, Piratvisuth T et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6: 531-61.
8. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-85.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661-2.
10. Liu CJ, Chuang WL, Lee CM et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009; 136: 496-504 e3.
11. Yeh ML, Hung CH, Huang JF et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One. 6: e20752.
12. Yu ML, Dai CY, Huang JF et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008; 47: 1884-93.
13. Marrone A, Zampino R, D'Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol. 2004; 41: 1064-5.
14. Okamoto H, Tokita H, Sakamoto M et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74 (Pt 11): 2385-90.
15. Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol. 20: 2955-61.
16. Kim YJ, Lee JW, Kim YS et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol. 17: 199-205.
17. Potthoff A, Wedemeyer H, Boecher WO et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008; 49: 688-94.
18. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-95.
19. Belloni L, Allweiss L, Guerrieri F et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 122: 529-37.
20. Dunn C, Brunetto M, Reynolds G et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007; 204: 667-80.
21. Yu ML, Lin SM, Lee CM et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology. 2006; 44: 1086-97.
22. Liu CJ. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. J Gastroenterol Hepatol. 29: 26-30.
23. Yu ML, Lee CM, Chuang WL et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis. 202: 86-92.
24. Cheng HR, Liu CJ, Tseng TC et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One. 8: e53008.